Grail has appointed George Golumbeski to serve as president of the Menlo Park, CA, cancer test developer. He has also joined Grail’s board of directors. Golumbeski was most recently executive vice president of business development at Celgene (NYSE: CELG). In May, Grail closed a $300 million Series C round of financing to continue its work to develop and validate a blood test that can detect cancer early.
UNDERWRITERS AND PARTNERS